• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受门诊肠外抗菌治疗患者再入院的风险因素:一项回顾性队列研究。

Risk factors for readmission among patients receiving outpatient parenteral antimicrobial therapy: a retrospective cohort study.

机构信息

Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC - Location VUmc, Amsterdam, The Netherlands.

Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, Amsterdam, The Netherlands.

出版信息

Int J Clin Pharm. 2022 Apr;44(2):557-563. doi: 10.1007/s11096-022-01379-7. Epub 2022 Feb 14.

DOI:10.1007/s11096-022-01379-7
PMID:35157228
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9007809/
Abstract

Background In the Netherlands, home treatment with intravenous antimicrobial therapy is a relatively new concept. Although several studies have shown that outpatient parenteral antimicrobial therapy (OPAT) can be administered safely, people receiving antimicrobials at home remain at risk for adverse events, including readmission. Aim The aim of our retrospective study was to identify risk factors for readmission in patients discharged with OPAT. Method Patients who were at least 18 years or older, discharged with OPAT between January 2016-December 2018 were included. Variables that were collected consisted of baseline demographics, complications, readmission within 30 days and treatment failure. Multivariate logistic regression analysis was performed to identify risk factors for readmission. Results A total of 247 patients were included; the most common reason for OPAT was bone and joint infections (17%). Penicillin (37%), cephalosporin (26%) and vancomycin/aminoglycoside (15%) were the most commonly prescribed antimicrobials. Among patients receiving medication subject to therapeutic drug monitoring (i.e. aminoglycosides or vancomycin), 51% (19/37) received weekly therapeutic drug monitoring. Receiving aminoglycosides or vancomycin (adjusted OR 2.05; 95% CI 1.30-3.25, p < 0.05) and infection of prosthetic material (adjusted OR 2.92, 95% CI 1.11-7.65, p < 0.05) were independent risk factors associated with readmission. Conclusion Although patients receiving medication subject to therapeutic drug monitoring are at higher risk of readmission, only half of the patients discharged with aminoglycosides or vancomycin were monitored according to IDSA guidelines. A specialized team in charge of monitoring patients with OPAT is more likely to increase the rate of monitoring to prevent readmissions and complications.

摘要

背景

在荷兰,家庭静脉内抗菌治疗是一个相对较新的概念。尽管多项研究表明,门诊患者接受抗菌药物治疗(OPAT)是安全的,但在家中接受抗菌药物治疗的患者仍存在不良事件的风险,包括再次入院。

目的

本回顾性研究的目的是确定接受 OPAT 出院患者再次入院的危险因素。

方法

研究纳入 2016 年 1 月至 2018 年 12 月期间接受 OPAT 治疗的年龄至少 18 岁以上的患者。收集的变量包括基线人口统计学数据、并发症、30 天内再入院和治疗失败。采用多变量逻辑回归分析确定再入院的危险因素。

结果

共纳入 247 例患者;OPAT 的最常见原因是骨和关节感染(17%)。最常开的抗菌药物是青霉素(37%)、头孢菌素(26%)和万古霉素/氨基糖苷类(15%)。在接受治疗药物监测的药物(即氨基糖苷类或万古霉素)的患者中,51%(19/37)接受了每周治疗药物监测。接受氨基糖苷类或万古霉素(调整后的 OR 2.05;95%CI 1.30-3.25,p<0.05)和植入物感染(调整后的 OR 2.92,95%CI 1.11-7.65,p<0.05)是与再入院相关的独立危险因素。

结论

尽管接受治疗药物监测药物的患者再入院风险较高,但只有一半接受氨基糖苷类或万古霉素治疗的患者按照 IDSA 指南进行了监测。负责监测 OPAT 患者的专门团队更有可能提高监测率,以预防再入院和并发症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfa/9007809/5fd796000e30/11096_2022_1379_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfa/9007809/95fe453db86b/11096_2022_1379_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfa/9007809/fca8d9601bef/11096_2022_1379_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfa/9007809/2d75fb1a5e6b/11096_2022_1379_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfa/9007809/5fd796000e30/11096_2022_1379_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfa/9007809/95fe453db86b/11096_2022_1379_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfa/9007809/fca8d9601bef/11096_2022_1379_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfa/9007809/2d75fb1a5e6b/11096_2022_1379_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cfa/9007809/5fd796000e30/11096_2022_1379_Fig4_HTML.jpg

相似文献

1
Risk factors for readmission among patients receiving outpatient parenteral antimicrobial therapy: a retrospective cohort study.接受门诊肠外抗菌治疗患者再入院的风险因素:一项回顾性队列研究。
Int J Clin Pharm. 2022 Apr;44(2):557-563. doi: 10.1007/s11096-022-01379-7. Epub 2022 Feb 14.
2
Prevalence and risk factors associated with readmission with acute kidney injury in patients receiving vancomycin outpatient parenteral antimicrobial therapy.接受万古霉素门诊肠外抗菌治疗的患者中,急性肾损伤再入院的患病率及相关风险因素。
J Clin Pharm Ther. 2022 Dec;47(12):2188-2195. doi: 10.1111/jcpt.13790. Epub 2022 Oct 18.
3
Predictors of Hospital Readmission in Patients Receiving Outpatient Parenteral Antimicrobial Therapy.接受门诊胃肠外抗菌治疗患者再次入院的预测因素
Pharmacotherapy. 2016 Aug;36(8):934-9. doi: 10.1002/phar.1799. Epub 2016 Jul 29.
4
Risk factors for readmission in patients discharged with outpatient parenteral antimicrobial therapy: a retrospective cohort study.接受门诊胃肠外抗菌治疗出院患者再入院的危险因素:一项回顾性队列研究。
BMC Pharmacol Toxicol. 2018 Aug 6;19(1):50. doi: 10.1186/s40360-018-0240-3.
5
Close Patient Follow-up Among Patients Receiving Outpatient Parenteral Antimicrobial Therapy.密切门诊肠外抗菌治疗患者的随访。
Clin Infect Dis. 2020 Jan 1;70(1):67-74. doi: 10.1093/cid/ciz150.
6
A retrospective analysis of adverse events among patients receiving daptomycin versus vancomycin during outpatient parenteral antimicrobial therapy.接受达托霉素与万古霉素门诊患者的药物不良反应回顾性分析。
Infect Control Hosp Epidemiol. 2018 Aug;39(8):947-954. doi: 10.1017/ice.2018.107. Epub 2018 Jun 12.
7
Self-Administered Outpatient Antimicrobial Infusion by Uninsured Patients Discharged from a Safety-Net Hospital: A Propensity-Score-Balanced Retrospective Cohort Study.安全网医院出院的未参保患者自我管理门诊抗菌药物输注:一项倾向评分平衡的回顾性队列研究。
PLoS Med. 2015 Dec 15;12(12):e1001922. doi: 10.1371/journal.pmed.1001922. eCollection 2015 Dec.
8
Nephrotoxicity Risk and Clinical Effectiveness of Continuous versus Intermittent Infusion Vancomycin Among Patients in an Outpatient Parenteral Antimicrobial Therapy Program.门诊肠外抗菌治疗项目中患者连续输注与间歇输注万古霉素的肾毒性风险及临床疗效
Pharmacotherapy. 2020 Apr;40(4):357-362. doi: 10.1002/phar.2381. Epub 2020 Mar 13.
9
Outpatient Versus Inpatient Intravenous Antimicrobial Therapy: A Population-Based Observational Cohort Study of Adverse Events and Costs.门诊与住院静脉抗菌治疗:一项基于人群的不良事件和成本观察性队列研究
Clin Infect Dis. 2022 Nov 30;75(11):1921-1929. doi: 10.1093/cid/ciac298.
10
Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study.达托霉素和万古霉素家庭输注治疗期间的不良事件、医疗保健干预措施及医疗保健利用情况:一项倾向评分匹配队列研究
J Antimicrob Chemother. 2014 May;69(5):1407-15. doi: 10.1093/jac/dkt512. Epub 2014 Jan 6.

引用本文的文献

1
Safety and Efficacy of Outpatient Parenteral Antibiotic Therapy (OPAT) in Patients With Infective Endocarditis: A Systematic Review and Meta-Analysis.门诊肠外抗生素治疗(OPAT)用于感染性心内膜炎患者的安全性和有效性:一项系统评价和荟萃分析
Clin Cardiol. 2025 May;48(5):e70147. doi: 10.1002/clc.70147.
2
Impact of a nurse practitioner-led dedicated outpatient parenteral antibiotic therapy clinic on patient outcomes and administrative workload: a retrospective cohort study.执业护士主导的门诊专用肠外抗生素治疗诊所对患者预后及行政工作量的影响:一项回顾性队列研究
Ther Adv Infect Dis. 2024 Dec 23;11:20499361241305308. doi: 10.1177/20499361241305308. eCollection 2024 Jan-Dec.
3

本文引用的文献

1
Quality Indicators for Appropriate Outpatient Parenteral Antimicrobial Therapy in Adults: A Systematic Review and RAND-modified Delphi Procedure.成人门诊患者适宜的肠外抗菌治疗质量指标:系统评价和 RAND 改良 Delphi 程序。
Clin Infect Dis. 2020 Mar 3;70(6):1075-1082. doi: 10.1093/cid/ciz362.
2
2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy.2018 年美国传染病学会门诊患者接受肠外抗菌治疗管理临床实践指南。
Clin Infect Dis. 2019 Jan 1;68(1):1-4. doi: 10.1093/cid/ciy867.
3
The impact of an infectious disease expert team on outpatient parenteral antimicrobial treatment in the Netherlands.
A Bundle of the "Top 10" Outpatient Parenteral Antimicrobial Therapy Publications in 2023.
2023年“十大”门诊肠外抗菌治疗出版物汇总
Open Forum Infect Dis. 2024 Oct 29;11(11):ofae635. doi: 10.1093/ofid/ofae635. eCollection 2024 Nov.
4
Current practices and challenges of outpatient parenteral antimicrobial therapy: a narrative review.门诊患者的肠外抗菌治疗的现状和挑战:叙事性综述。
J Antimicrob Chemother. 2024 Sep 3;79(9):2083-2102. doi: 10.1093/jac/dkae177.
5
Dalbavancin as an alternative to traditional outpatient parenteral antimicrobial therapy for deep gram-positive infections - an observational, retrospective review.达巴万星作为深部革兰氏阳性菌感染传统门诊胃肠外抗菌治疗的替代方案——一项观察性回顾性研究。
Ther Adv Infect Dis. 2024 Apr 19;11:20499361241245523. doi: 10.1177/20499361241245523. eCollection 2024 Jan-Dec.
6
Creation and Validation of an Automated Registry for Outpatient Parenteral Antibiotics.门诊胃肠外抗生素自动登记系统的创建与验证
Open Forum Infect Dis. 2024 Jan 12;11(2):ofae004. doi: 10.1093/ofid/ofae004. eCollection 2024 Feb.
7
Prolonged use of linezolid in bone and joint infections: a retrospective analysis of adverse effects.利奈唑胺在骨和关节感染中的长期应用:不良事件的回顾性分析。
J Antimicrob Chemother. 2023 Nov 6;78(11):2660-2666. doi: 10.1093/jac/dkad276.
8
A Bundle of the Top 10 OPAT Publications in 2022.2022年十大门诊抗菌药物治疗(OPAT)出版物汇总。
Open Forum Infect Dis. 2023 May 23;10(6):ofad283. doi: 10.1093/ofid/ofad283. eCollection 2023 Jun.
9
A single centre experience of prosthetic joint infection outcomes with outpatient parenteral antimicrobial therapy.门诊胃肠外抗菌治疗的人工关节感染结局的单中心经验
Heliyon. 2023 Apr 11;9(4):e15212. doi: 10.1016/j.heliyon.2023.e15212. eCollection 2023 Apr.
10
Successful Integration of Clinical Pharmacists in an OPAT Program: A Real-Life Multidisciplinary Circuit.临床药师在门诊抗菌药物治疗(OPAT)项目中的成功整合:一个实际的多学科案例
Antibiotics (Basel). 2022 Aug 19;11(8):1124. doi: 10.3390/antibiotics11081124.
传染病专家团队对荷兰门诊胃肠外抗菌治疗的影响。
Int J Clin Pharm. 2019 Feb;41(1):49-55. doi: 10.1007/s11096-018-0751-4. Epub 2018 Nov 26.
4
Cost-utility analysis of outpatient parenteral antimicrobial therapy (OPAT) in the Brazilian national health system.巴西国家卫生系统中门诊肠外抗菌治疗(OPAT)的成本-效用分析。
Expert Rev Pharmacoecon Outcomes Res. 2019 Jun;19(3):341-352. doi: 10.1080/14737167.2019.1541404. Epub 2018 Nov 5.
5
Impact of the implementation of a nurse-managed outpatient parenteral antibiotic therapy (OPAT) system in Baltimore: a case study demonstrating cost savings and reduction in re-admission rates.巴尔的摩实施护士管理的门诊静脉用抗生素治疗 (OPAT) 系统的影响:一项证明节省成本和降低再入院率的案例研究。
J Antimicrob Chemother. 2018 Nov 1;73(11):3181-3188. doi: 10.1093/jac/dky294.
6
Risk factors for readmission in patients discharged with outpatient parenteral antimicrobial therapy: a retrospective cohort study.接受门诊胃肠外抗菌治疗出院患者再入院的危险因素:一项回顾性队列研究。
BMC Pharmacol Toxicol. 2018 Aug 6;19(1):50. doi: 10.1186/s40360-018-0240-3.
7
Rates of and Risk Factors for Adverse Drug Events in Outpatient Parenteral Antimicrobial Therapy.门诊肠外抗菌治疗药物不良事件的发生率和危险因素。
Clin Infect Dis. 2018 Jan 6;66(1):11-19. doi: 10.1093/cid/cix733.
8
Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service.门诊静脉用抗生素治疗 (OPAT) 的临床疗效、成本分析和患者接受度:谢菲尔德(英国)OPAT 服务十年来的经验。
Int J Antimicrob Agents. 2018 Jan;51(1):26-32. doi: 10.1016/j.ijantimicag.2017.03.016. Epub 2017 Jun 30.
9
Impact of Antimicrobial Stewardship for Pediatric Outpatient Parenteral Antibiotic Therapy.儿科门诊患者抗菌药物治疗中抗菌药物管理的影响。
J Pediatric Infect Dis Soc. 2018 May 15;7(2):e34-e36. doi: 10.1093/jpids/pix038.
10
Patient satisfaction in an outpatient parenteral antimicrobial therapy (OPAT) unit practising predominantly self-administration of antibiotics with elastomeric pumps.门诊肠外抗菌治疗(OPAT)单元中以弹性泵自我给药为主的患者满意度。
Eur J Clin Microbiol Infect Dis. 2017 Aug;36(8):1387-1392. doi: 10.1007/s10096-017-2944-5. Epub 2017 Mar 11.